FDA-Approved Cannabis Drug Rakes in $296 Million in First Year of Sales

January 22, 2020 16:00:09

Cannabidiol is a chemical that’s extracted from the hemp plant, and it has taken the world by storm. While people often confuse hemp with its illicit cousin marijuana, they differ in one critical way. The 2018 Farm Bill legalized industrial hemp, defining it as cannabis with less than 0.3% THC. It is the chemical responsible for marijuana’s psychoactive high.

CBD takes the cake in other ways. Said to be chock-full of medicinal properties, it is used to help manage a variety of ailments, ranging from chronic pain and high blood pressure to anxiety. Unfortunately, there’s limited scientific evidence to…


About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.